Actively Recruiting
Evaluating Safety and Effectiveness of NDV01 KIT for High-Grade Non-Muscle Invasive Bladder Cancer
Led by Relmada Therapeutics, Inc. · Updated on 2026-09-02
70
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of NDV01 KIT, a combined drug therapy of gemcitabine HCl and docetaxel, given directly into the bladder for patients with high-grade Non-Muscle Invasive Bladder Cancer NMIBC. This prospective, single-arm study focuses on patients who are either ineligible for or have chosen not to undergo radical cystectomy. The study also includes a pharmacokinetic sub-study to assess how the drugs are absorbed systemically. Participants receive NDV01 KIT through a catheter in two phases an initial treatment phase consisting of six biweekly instillations on Days 1, 14, 28, 42, 56, and 70, followed by a maintenance phase with monthly instillations up to 12 months. Patients who do not achieve a complete response by Day 100 may undergo a second induction cycle before continuing maintenance. The pharmacokinetic sub-study involves up to 15 blood samples during the first treatment cycle. Throughout the study, participants will be closely monitored for safety and treatment response. Assessments include a Primary Disease Evaluation around Day 100 and ongoing evaluations of complete response durability, event-free survival, cystectomy incidence, and overall survival. Safety is tracked through adverse event monitoring at any time during the study. Participants will be involved for up to 12 months, with long-term follow-up to evaluate response durability.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Research Team
S
Scott White
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here